株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体薬物複合体 (ADC) の世界市場:売上・パイプライン分析・市場予測

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023

発行 RNCOS E-Services Pvt. Ltd. 商品コード 682114
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.17円で換算しております。
Back to Top
抗体薬物複合体 (ADC) の世界市場:売上・パイプライン分析・市場予測 Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023
出版日: 2018年08月14日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界の抗体薬物複合体 (ADC) 市場について分析し、ADCの概要、全体的な市場規模の動向見通し 、主な市販薬・パイプライン製品、市場成長の促進要因と課題、および主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 抗体薬物複合体 (ADC) :イントロダクション

第4章 世界の抗体薬物複合体 (ADC) 市場展望

第5章 上市済みの抗体薬物複合体 (ADC)

  • ADCETRIS
  • Kadcyla
  • Mylotarg
  • Besponsa

第6章 抗体薬物複合体 (ADC) のパイプライン分析

  • 企業別
    • 位相別
    • 症状別
    • 薬剤別
    • リンカー別
    • 技術別
  • 研究機関別

第7章 促進要因・課題

  • 促進要因
  • 課題

第8章 パイプラインにおける主要な潜在的ADC

  • 企業別
  • 研究機関別

第9章 動向・発展

  • 血液悪性腫瘍治療の先頭を走るADC
  • 乳がん患者へメリットを提供するADC

第10章 世界のADC産業における戦略的アライアンス

第11章 競合評価

  • Seattle Genetics, Inc.
  • F. Hoffman-La Roche Ltd.
  • Pfizer Inc.
  • ImmunoGen, Inc.
  • Bayer AG
  • 武田薬品工業
  • Immunomedics, Inc.
  • Oxford BioTherapeutics
  • Concortis Biotherapeutics
  • NBE-Therapeutics
目次

Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.

According to the RNCOS report entitled "Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023", the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry's growth.

The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC)-An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates

  • 5.1. ADCETRIS
  • 5.2. Kadcyla
  • 5.3. Mylotarg
  • 5.4. Besponsa

6. Antibody Drug Conjugates Pipeline Analysis

  • 6.1. By Companies
    • 6.1.1. By Clinical Phase
    • 6.1.2. By Indication
    • 6.1.3. By Drug
    • 6.1.4. By Type of Linker
    • 6.1.5. By Technology
  • 6.2. By Research Organizations
    • 6.2.1. By Phase
    • 6.2.2. By Indication
    • 6.2.3. By Drug
    • 6.2.4. By Type of Linker
    • 6.2.5. By Technology

7. Drivers and Challenges

  • 7.1. Drivers
    • 7.1.1. Rising Global Cancer Epidemics
    • 7.1.2. Advances in Linking Technologies Re-Instills Hope in ADC
    • 7.1.3. Efforts towards Patent Protection to Drive ADC Market
    • 7.1.4. Increasing Demand for Antibody Drug Conjugates
  • 7.2. Challenges
    • 7.2.1. Production Hurdles and Cost
    • 7.2.2. Inadequacy of Experienced Manufacturers
    • 7.2.3. Regulatory Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

  • 8.1. By Companies
    • 8.1.1. Glembatumumab Vedotin Therapeutics/CDX-011-Celldex
    • 8.1.2. Coltuximab Ravtansine/SAR3419-ImmunoGen Inc.
    • 8.1.3. Indatuximab Ravtansine/BT-062-Biotest AG
    • 8.1.4. Anti-PSMA ADC Therapeutic-Progenics Pharmaceuticals
    • 8.1.5. Polatuzumab Vedotin/RG7596-F. Hoffman-La Roche Ltd.
    • 8.1.6. DMUC-4064A/RG7882-F. Hoffman-La Roche Ltd.
    • 8.1.7. Mirvetuximab Soravtansine/IMGN853-ImmunoGen Inc.
  • 8.2. By Research Organizations
    • 8.2.1. SGM-101-SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
    • 8.2.2. MOC31-PE-Creative Biolabs in Collaboration with Oslo University Hospital

9. Trends and Developments

  • 9.1. ADC at the Forefront of Treating Hematological Malignancies
  • 9.2. ADCs Proving Advantageous for Breast Cancer Patients

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

11. Competitive Assessment

  • 11.1. Seattle Genetics, Inc.
  • 11.2. F. Hoffman-La Roche Ltd.
  • 11.3. Pfizer Inc.
  • 11.4. ImmunoGen, Inc.
  • 11.5. Bayer AG
  • 11.6. Takeda Pharmaceutical Company Limited
  • 11.7. Immunomedics, Inc.
  • 11.8. Oxford BioTherapeutics
  • 11.9. Concortis Biotherapeutics
  • 11.10. NBE-Therapeutics

List of Figures:

  • Figure 3-1: ADC - Mechanism of Action
  • Figure 4-1: Global - ADC Market (Billion US$), 2016, 2017 & 2023
  • Figure 5-1: Global - ADCETRIS Sales (Million US$), 2016 & 2017
  • Figure 5-2: Global - Kadcyla Sales (Million US$), 2016 & 2017
  • Figure 6-1: Global - ADCs Pipeline by Developing Organizations (%), 2017
  • Figure 6-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2017
  • Figure 6-3: Global - ADC Pipeline of Companies by Indication (%), 2017
  • Figure 6-4: Global - ADC Pipeline of Companies by Drug (%), 2017
  • Figure 6-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2017
  • Figure 6-6: Global - ADC Pipeline of Companies by Technology (%), 2017
  • Figure 6-7: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2017
  • Figure 6-8: Global - ADC Pipeline of Research Organization by Indication (%), 2017
  • Figure 6-9: Global - ADC Pipeline of Research Organization by Drug (%), 2017
  • Figure 6-10: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2017
  • Figure 6-11: Global - ADC Pipeline of Research Organization by Technology (%), 2017
  • Figure 11-1: F. Hoffman-La Roche Ltd. - Group Sales Breakup by Business Segments (%), 2016
  • Figure 11-2: Pfizer Inc. - Revenue Breakup by Business Segments (%), 2016
  • Figure 11-3: Pfizer Inc. - Revenue Breakup by Geography (%), 2016
  • Figure 11-4: Bayer AG - Sales Breakup by Business Segments (%), 2016
  • Figure 11-5: Bayer AG - Net Sales Breakup by Geography (%), 2016
  • Figure 11-6: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
  • Figure 11-7: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2017

List of Tables:

  • Table 5-1: Global - Incidence of Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
  • Table 5-2: Global - Incidence of Non-Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
  • Table 5-3: Major Ongoing Trials for ADCETRIS
  • Table 5-4: Global - Incidence of Breast Cancer, 2012, 2015, 2020, & 2025
  • Table 5-5: Major Ongoing Trials for Kadcyla
  • Table 5-6: Major Ongoing Trials for Mylotarg
  • Table 5-7: Major Ongoing Trials for Besponsa
  • Table 6-1: Global - ADC Pipeline of Companies
  • Table 6-2: Global - ADC Pipeline of Research Organization
  • Table 10-1: Major Strategic Alliances in the Global Antibody Drug Conjugates Industry (2014-2017)
  • Table 11-1: Seattle Genetics, Inc. - Key Financials (Million US$), 2014-2016
  • Table 11-2: Seattle Genetics, Inc. - ADC Product Portfolio
  • Table 11-3: Seattle Genetics, Inc. - ADCs in Pipeline
  • Table 11-4: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2014-2016
  • Table 11-5: F. Hoffman-La Roche Ltd. - ADC Product Portfolio
  • Table 11-6: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
  • Table 11-7: Pfizer Inc. - Key Financials (Million US$), 2014-2016
  • Table 11-8: Pfizer Inc. - ADC Product Portfolio
  • Table 11-9: Pfizer Inc. - ADCs in Pipeline
  • Table 11-10: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
  • Table 11-11: ImmunoGen, Inc. - ADCs in Pipeline
  • Table 11-12: Bayer AG - Key Financials (Million US$), 2014-2016
  • Table 11-13: Bayer AG - ADCs in Pipeline
  • Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
  • Table 11-15: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
  • Table 11-16: Immunomedics, Inc. - Key Financials (Million US$), 2015-2017
  • Table 11-17: Immunomedics, Inc. - ADCs in Pipeline
  • Table 11-18: Oxford BioTherapeutics - ADCs in Pipeline
  • Table 11-19: Concortis Biotherapeutics - ADCs in Pipeline
  • Table 11-20: NBE-Therapeutics - ADCs in Pipeline
Back to Top